This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Arcus Biosciences (RCUS) and Dyne Therapeutics (DYN)

Tipranks - Tipranks - Fri Jun 5, 8:28AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medtronic (MDT), Arcus Biosciences (RCUS) and Dyne Therapeutics (DYN) with bullish sentiments.

Claim 55% Off TipRanks

Medtronic (MDT)

In a report released today, Vijay Kumar from Evercore ISI maintained a Buy rating on Medtronic, with a price target of $106.00. The company’s shares closed last Thursday at $79.87.

According to TipRanks.com, Kumar is a 3-star analyst with an average return of 1.3% and a 45.5% success rate. Kumar covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, West Pharmaceutical Services, and Caris Life Sciences, Inc. ;'>

Currently, the analyst consensus on Medtronic is a Moderate Buy with an average price target of $99.32, which is a 27.4% upside from current levels. In a report released today, BTIG also upgraded the stock to Buy with a $90.00 price target.

See the top stocks recommended by analysts >>

Arcus Biosciences (RCUS)

Truist Financial analyst Supawat Thongthip maintained a Buy rating on Arcus Biosciences today. The company’s shares closed last Thursday at $23.99.

Thongthip has an average return of 1.9% when recommending Arcus Biosciences. ;'>

According to TipRanks.com, Thongthip is ranked #8779 out of 12292 analysts.

Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $37.67, which is a 57.9% upside from current levels. In a report released today, LifeSci Capital also initiated coverage with a Buy rating on the stock with a $46.00 price target.

Dyne Therapeutics (DYN)

In a report released today, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Dyne Therapeutics, with a price target of $33.00. The company’s shares closed last Thursday at $17.75.

According to TipRanks.com, Clark-Gartner is a 5-star analyst with an average return of 22.4% and a 54.3% success rate. Clark-Gartner covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Crinetics Pharmaceuticals, and Viridian Therapeutics. ;'>

Dyne Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $37.91, implying an 110.7% upside from current levels. In a report issued on May 21, H.C. Wainwright also maintained a Buy rating on the stock with a $50.00 price target.

Read More on MDT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).